Xenamed is a pharmaceutical drug development company founded in 2016. Xenamed develops products at UEL and collaborates with contract manufacturing organizations for manufacturing clinical supplies, submission batches, and eventually commercialization. In addition to research and development, Xenamed manages every step of the FDA approval process for their products.
Xenamed develops both brand name and generic products for diverse therapeutic areas. They also work on several dosage forms other than tablets and capsules. Usually, these products have significant technical challenges.
In the short time in which Xenamed has been operating, Xenamed scientists have developed novel products and filed a number of patents in exciting therapeutic areas. Some of these products are being readied to be tested in the first human trials.
Currently, Xenamed employs formulators and analytical chemists and by the virtue of its model, its staff get a wide variety of experience beyond their particular expertise. This includes contributing to clinical, regulatory and production issues. Xenamed also collaborates with the UMN on projects and provides internships.
Besides the science, Xenamed is looking to address patient needs and improve patient outcomes. With a full pipeline of projects, Xenamed provides an exciting working environment.
This UEL Highlight is by Amanda Hayward, a fourth-year Ph.D. candidate in the Biochemistry, Molecular Biology and Biophysics department at UMN-Twin Cities. You can reach her at AHayward@uelmn.org.